JP2021512649A5 - - Google Patents
Info
- Publication number
- JP2021512649A5 JP2021512649A5 JP2020564045A JP2020564045A JP2021512649A5 JP 2021512649 A5 JP2021512649 A5 JP 2021512649A5 JP 2020564045 A JP2020564045 A JP 2020564045A JP 2020564045 A JP2020564045 A JP 2020564045A JP 2021512649 A5 JP2021512649 A5 JP 2021512649A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- regulatory element
- acid sequence
- sequence
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023188066A JP7776477B2 (ja) | 2018-02-05 | 2023-11-02 | 転写調節要素及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626561P | 2018-02-05 | 2018-02-05 | |
| US62/626,561 | 2018-02-05 | ||
| PCT/US2019/016692 WO2019153009A1 (en) | 2018-02-05 | 2019-02-05 | Transcription regulatory elements and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188066A Division JP7776477B2 (ja) | 2018-02-05 | 2023-11-02 | 転写調節要素及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512649A JP2021512649A (ja) | 2021-05-20 |
| JP2021512649A5 true JP2021512649A5 (enExample) | 2022-02-09 |
| JP7381494B2 JP7381494B2 (ja) | 2023-11-15 |
Family
ID=67478520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564045A Active JP7381494B2 (ja) | 2018-02-05 | 2019-02-05 | 転写調節要素及びその使用 |
| JP2023188066A Active JP7776477B2 (ja) | 2018-02-05 | 2023-11-02 | 転写調節要素及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023188066A Active JP7776477B2 (ja) | 2018-02-05 | 2023-11-02 | 転写調節要素及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12296026B2 (enExample) |
| EP (1) | EP3749756A4 (enExample) |
| JP (2) | JP7381494B2 (enExample) |
| CN (1) | CN111936621B (enExample) |
| MA (1) | MA51753A (enExample) |
| WO (1) | WO2019153009A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018281280B2 (en) | 2017-06-07 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| CA3086942A1 (en) * | 2018-02-07 | 2019-08-15 | Genethon | Hybrid regulatory elements |
| CN112040985A (zh) | 2018-02-07 | 2020-12-04 | 瑞泽恩制药公司 | 用于递送治疗性蛋白质的方法和组合物 |
| EP3793591A1 (en) | 2018-05-17 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Anti-cd63 antibodies, conjugates, and uses thereof |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| KR20210148273A (ko) * | 2019-04-08 | 2021-12-07 | 제네똥 | 근육 발현을 위한 하이브리드 프로모터 |
| AU2020372429A1 (en) * | 2019-10-25 | 2022-04-28 | Audentes Therapeutics, Inc. | Compositions and methods for treating glycogen storage disorders |
| WO2021102107A1 (en) * | 2019-11-19 | 2021-05-27 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders |
| EP4107259A1 (en) * | 2020-02-18 | 2022-12-28 | Vrije Universiteit Brussel | Novel combination of nucleic acid regulatory elements and methods and uses thereof |
| GB202013194D0 (en) * | 2020-08-24 | 2020-10-07 | Combigene Ab | Gene therapy for lipodystrophy |
| CA3216419A1 (en) * | 2021-04-23 | 2022-10-27 | Greg NACHTRAB | Tissue-targeted modified aav capsids and methods of use thereof |
| AR126660A1 (es) * | 2021-07-28 | 2023-11-01 | Univ Brussel Vrije | Mejorando la eficacia de la terapia génica dirigida a músculos |
| WO2023012313A1 (en) * | 2021-08-04 | 2023-02-09 | Genethon | Hybrid promoters for gene expression in muscles and in the cns |
| TW202400796A (zh) * | 2022-03-11 | 2024-01-01 | 美商同源醫藥公司 | 雙向雙重啟動子表現載體及其用途 |
| TW202409290A (zh) * | 2022-06-27 | 2024-03-01 | 美商安斯泰來基因治療股份有限公司 | 用於治療肌強直性營養不良之組合物及方法 |
| EP4598590A4 (en) * | 2022-10-08 | 2026-05-27 | Lingyi Biotech Co Ltd | CONSTRUCTION TO IMPROVE GENE EXPRESSION |
| WO2025004002A2 (en) | 2023-06-30 | 2025-01-02 | Takeda Pharmaceutical Company Limited | Treatment of pompe disease |
| CN118064436B (zh) * | 2024-04-18 | 2024-07-26 | 上海凌医生物科技有限公司 | 一种增强基因表达的嵌合启动子 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1390490B1 (en) * | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
| US8021875B2 (en) | 2001-08-27 | 2011-09-20 | Roche Madison Inc. | Methods for expression of transgenes |
| ES2436741T3 (es) | 2004-09-22 | 2014-01-07 | St. Jude Children's Research Hospital | Expresión mejorada de Factor IX en vectores de terapia génica |
| US20070161031A1 (en) | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
| EP4124346A3 (en) | 2012-06-19 | 2023-04-19 | University of Florida Research Foundation, Inc. | Compositions and methods for treating diseases |
| CN105229144A (zh) * | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | 通过组合的遗传工程和化学工程经由正向编程产生肝细胞 |
| AU2015208247B2 (en) * | 2014-01-21 | 2021-05-27 | Universiteit Gent | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
| US10781459B2 (en) | 2014-06-20 | 2020-09-22 | University Of Florida Research Foundation, Incorporated | Methods of packaging multiple adeno-associated virus vectors |
| EP3285788B1 (en) | 2015-04-23 | 2024-12-18 | University of Massachusetts | Modulation of aav vector transgene expression |
| JP2018535929A (ja) * | 2015-09-24 | 2018-12-06 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第ｖｉｉｉ因子ベクター、関連ウイルス粒子、及びそれらを含む治療的製剤 |
-
2019
- 2019-02-05 CN CN201980015960.6A patent/CN111936621B/zh active Active
- 2019-02-05 MA MA051753A patent/MA51753A/fr unknown
- 2019-02-05 WO PCT/US2019/016692 patent/WO2019153009A1/en not_active Ceased
- 2019-02-05 JP JP2020564045A patent/JP7381494B2/ja active Active
- 2019-02-05 US US16/966,521 patent/US12296026B2/en active Active
- 2019-02-05 EP EP19748361.3A patent/EP3749756A4/en active Pending
-
2023
- 2023-11-02 JP JP2023188066A patent/JP7776477B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508182A5 (enExample) | ||
| Zincarelli et al. | Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection | |
| JP6619454B2 (ja) | キャプシド | |
| US10413598B2 (en) | Factor IX gene therapy | |
| JP2020522269A5 (enExample) | ||
| JP2022549140A5 (enExample) | ||
| JP2021511803A5 (enExample) | ||
| JP7541027B2 (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| RU2018116076A (ru) | Модифицированные гены атаксии фридрейха и векторы для генной терапии | |
| JP2022529631A5 (enExample) | ||
| JP2007507223A5 (enExample) | ||
| JP2022541070A5 (enExample) | ||
| JP2021522173A5 (enExample) | ||
| US20250297285A1 (en) | Transgene cassettes designed to express a human mecp2 gene | |
| JP2022551744A5 (enExample) | ||
| JP2020509786A5 (enExample) | ||
| JP2023537358A5 (enExample) | ||
| JP2024512483A5 (enExample) | ||
| JP2023524414A5 (enExample) | ||
| JP2021520811A5 (enExample) | ||
| JP2023529371A5 (enExample) | ||
| JP2023520927A5 (enExample) | ||
| JP2023539631A5 (enExample) | ||
| JP2022548270A5 (enExample) | ||
| JP2023541444A5 (enExample) |